Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective

por Rose, Peter G.
Publicado 2022

Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing()

por Rose, Peter G., Sierk, Anne
Publicado 2019

Pegylated liposomal doxorubicin in ovarian cancer

por Green, Andrew E, Rose, Peter G
Publicado 2006

Adverse post-operative outcomes in Jehovah's witnesses with gynecologic cancer within 30 days of surgery: A single institution review of 36 cases()

por Moulton, Laura J., Rose, Peter G., Mahdi, Haider
Publicado 2017

To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?

por Rose, Peter G, Chambers, Laura M, Kuznicki, Michelle
Publicado 2021

Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions

por Maurer, Kathryn, Michener, Chad, Mahdi, Haider, Rose, Peter G.
Publicado 2017

Lymph node metastasis and pattern of recurrence in clinically early stage endometrial cancer with positive lymphovascular space invasion

por Mahdi, Haider, Jernigan, Amelia, Nutter, Benjamin, Michener, Chad, Rose, Peter G.
Publicado 2015

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series

por Rose, Peter G., Feldman, Myra, Podzielinski, Iwona, Petty, Aaron P., Vargas, Roberto
Publicado 2023

The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone

por Mahdi, Haider, Nutter, Benjamin, Abdul-Karim, Fadi, Amarnath, Sudha, Rose, Peter G
Publicado 2016

The Overtreatment and Cost Effectiveness of Primary versus Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC)

por Rose, Peter G, Yao, Meng, Chambers, Laura M, Mei, Lin, Le, Phuc
Publicado 2021

Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer population()

por Kuznicki, Michelle L., Bennett, Carrie, Yao, Meng, Joehlin-Price, Amy, Rose, Peter G., Mahdi, Haider
Publicado 2020

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma

por Hunt, Jonathan T., Chambers, Laura M., Yao, Meng, Joehlin-Price, Amy, Debernardo, Robert, Rose, Peter G.
Publicado 2021

Case Report: Circulating Tumor DNA Fraction Analysis Using Ultra-Low-Pass Whole-Genome Sequencing Correlates Response to Chemoradiation and Recurrence in Stage IV Small-Cell Carcin...

por Abbas, Ata, Gruner, Morgan, Karohl, Jennifer, Rose, Peter G., Joehlin-Price, Amy, Stover, Daniel, Mahdi, Haider
Publicado 2021

High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition

por Ni, Ying, Soliman, Ahmed, Joehlin-Price, Amy, Rose, Peter G., Vlad, Anda, Edwards, Robert P., Mahdi, Haider
Publicado 2021

Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma

por Chambers, Laura M., Chau, Danielle, Yao, Meng, Costales, Anthony B., Rose, Peter G., Michener, Chad M., Debernardo, Robert, Vargas, Roberto
Publicado 2021

Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemother...

por Morton, Molly, Chambers, Laura M., Costales, Anthony B., Chichura, Anna, Gruner, Morgan, Horowitz, Max P., Rose, Peter G., Yao, Meng, Debernardo, Robert, Michener, Chad
Publicado 2021

Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer

por Chambers, Laura M., Yao, Meng, Morton, Molly, Gruner, Morgan, Chichura, Anna, Costales, Anthony B., Horowitz, Max, Rose, Peter G., Michener, Chad M., Debernardo, Robert
Publicado 2022

LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer

por Dey, Goutam, Bharti, Rashmi, Braley, Chad, Alluri, Ravi, Esakov, Emily, Crean-Tate, Katie, McCrae, Keith, Joehlin-Price, Amy, Rose, Peter G., Lathia, Justin, Gong, Zihua, Reizes, Ofer
Publicado 2023

Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer

por Connor, Elizabeth V., Saygin, Caner, Braley, Chad, Wiechert, Andrew C., Karunanithi, Sheelarani, Crean-Tate, Katie, Abdul-Karim, Fadi W., Michener, Chad M., Rose, Peter G., Lathia, Justin D., Reizes, Ofer
Publicado 2019

Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition

por Al-Sudani, Hussein, Ni, Ying, Jones, Philip, Karakilic, Huseyin, Cui, Lei, Johnson, Lisa D. S., Rose, Peter G., Olawaiye, Alexander, Edwards, Robert P., Uger, Robert A., Lin, Gloria H. Y., Mahdi, Haider
Publicado 2023